[HTML][HTML] Towards a universal influenza vaccine: different approaches for one goal

GA Sautto, GA Kirchenbaum, TM Ross - Virology journal, 2018 - Springer
Influenza virus infection is an ongoing health and economic burden causing epidemics with
pandemic potential, affecting 5–30% of the global population annually, and is responsible …

Universal influenza virus vaccines: what needs to happen next?

C Trucchi, C Paganino, D Amicizia, A Orsi… - Expert Opinion on …, 2019 - Taylor & Francis
Introduction: Influenza occurs worldwide and causes significant disease burden in terms of
morbidity, associated complications, hospitalizations, and deaths. Vaccination constitutes …

[HTML][HTML] A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve

Y Fu, Z Zhang, J Sheehan, Y Avnir, C Ridenour… - Nature …, 2016 - nature.com
Understanding the natural evolution and structural changes involved in broadly neutralizing
antibody (bnAb) development holds great promise for improving the design of prophylactic …

[HTML][HTML] An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus

KH Kim, J Kim, M Ko, JY Chun, H Kim, S Kim… - PLoS …, 2019 - journals.plos.org
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease
localized to China, Japan, and Korea that is characterized by severe hemorrhage and a high …

[HTML][HTML] A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis

PK Kim, JS Ahn, CM Kim, JM Seo, SJ Keum, HJ Lee… - Plos one, 2021 - journals.plos.org
Post-exposure prophylaxis (PEP) is highly effective in preventing disease progression of
rabies when used in timely and appropriate manner. The key treatment for PEP is infiltration …

[HTML][HTML] Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus

DV Shcheblyakov, DV Voronina, IA Favorskaya… - Acta …, 2024 - ncbi.nlm.nih.gov
Monoclonal antibodies and recombinant antibody fragments are a very promising
therapeutic tool to combat infectious diseases. Due to their unique paratope structure …